Summary
This technical report provides an overview of Color's hereditary genetic testing services, detailing the suite of clinically actionable genetic tests aimed at supporting informed care in oncology, pharmacogenomics, and adult preventive health. The report outlines the testing methodology, which is built on a next-generation sequencing (NGS) platform, emphasizing the importance of accurate variant classification and reporting. It describes the types of genetic tests offered, including those for hereditary cancer risks and pharmacogenomics, and highlights the clinical validity and utility of the tests based on established medical guidelines. The document also explains the sequencing technology and bioinformatics pipeline employed to ensure high-quality results. Additionally, it discusses the interpretation framework used for variant classification, which adheres to guidelines from recognized organizations. The report concludes by addressing the limitations of the testing technology and the inherent challenges in genomic sequencing, ensuring that healthcare providers are well-informed about the capabilities and constraints of the genetic testing services provided by Color.
